Abstract:Amantadine and modafinil are neurostimulants that may improve cognitive and functional recovery post-stroke, but the existing study results vary, and no comprehensive review has been published. This systematic review describes amantadine and modafinil administration practices post-stroke, evaluates timing and impact on clinical effectiveness measures, and identifies the incidence of potential adverse drug effects. A librarian-assisted search of the MEDLINE (PubMed) and EMBASE databases identified all English-language publications with "amantadine" or "modafinil" in the title or abstract from inception through February 1, 2020. Publications meeting predefined Patient, Intervention, Comparator, Outcome (PICO) criteria were included: Patients (≥ 18 years of age post-stroke); Intervention (amantadine or modafinil administration); Comparison (pretreatment baseline or control group); Outcomes (cognitive or functional outcome). Amantadine and modafinil administration practices, cognitive and functional outcomes, and incidence of potential adverse drug effects were collected following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidance. Quantitative analyses were not performed due to heterogeneity in the clinical effectiveness measures; descriptive data are presented as number (percent) or median (interquartile range). Of 12,620 publications initially identified, 10 amantadine publications (n = 121 patients) and 12 modafinil publications (n = 120 patients) were included. Amantadine was initiated 39 (16, 385) days post-stroke, with most common initial doses of 100 mg once or twice daily (range 100-200 mg/day), and final daily dose of 200 (188, 200) mg/day. Modafinil was initiated 170 (17, 496) days post-stroke, with initial and final daily doses of 100 (100, 350) mg/day and 200 (100, 350) mg/day, respectively. The most common indication was consciousness disorders for amantadine (n = 3/10 publications; 30%) and fatigue for modafinil (n = 5/12; 42%). Forty unique clinical effectiveness measures (1.8 per study) with 141 domains (6.4 per study) were described across all studies. A positive response in at least one clinical effectiveness measure was reported in 70% of amantadine publications and 83% of modafinil publications. Only one publication each for amantadine (10%; n = 5 patients) and modafinil (8%; n = 21 patients) studied acutely hospitalized or ICU patients; both were randomized studies showing improvements in neurocognitive function for amantadine and fatigue for modafinil. Potential adverse drug effects were reported in approximately 50% of publications, most commonly visual hallucinations with amantadine (2% of patients) and dizziness (5% of patients) and dry eyes or mouth (5% of patients). Amantadine and modafinil may improve cognitive and functional recovery post-stroke, but higher-quality data are needed to confirm this conclusion, especially in the acute care setting.

Effects of Amantadine Sulfate on Motor Impairment and Execution of Motor Sequences in Patients With Parkinson Disease

Amantadine improves water maze performance without affecting motor behavior following traumatic brain injury in rats

Amantadine enhances nigrostriatal and mesolimbic dopamine function in the rat brain in relation to motor and exploratory activity

Utilization Patterns of Amantadine in Parkinson’s Disease Patients Enrolled in the French COPARK Study

Informing future randomized controlled trials of amantadine hydrochloride in neurocritical care and post-neurocritical care stroke patients through a retrospective study

Amantadine treatment is associated with improved consciousness in patients with non-traumatic brain injury

Plasma Concentrations of L-dopa and 3-Methoxydopa and Improvement in Clinical Ratings and Motor Performance in Patients with Parkinsonism Treated with L-dopa Alone or in Combination with Amantadine.

Amantadine and Modafinil as Neurostimulants During Post-stroke Care: A Systematic Review

Feasibility and Positive Effects of Scalp Acupuncture for Modulating Motor and Cerebral Activity in Parkinson's Disease: A Pilot Study.

Effects of Intracerebral Aminophylline Dosing on Catalepsy and Gait in an Animal Model of Parkinson's Disease

Amantadine for dyskinesia in patients affected by severe Parkinson's disease

Does amantadine maintain function in long-established brain injury? A single case experimental design

Effect of Amantadine on the Activity of Mitochondrial Glutamate Carrier in Patients with Parkinson's Disease

Amantadine and Modafinil as Neurostimulants Following Acute Stroke: A Retrospective Study of Intensive Care Unit Patients

Additive effect of cerebrolysin and amantadine on disorders of consciousness secondary to acquired brain injury: A retrospective case-control study

Early Amantadine Treatment Reduces the Risk of Death in Patients with Large Hemisphere Infarctions:A Chinese Hospital-Based Study

Medication improves velocity, reaction time, and movement time but not amplitude or error during memory-guided reaching in Parkinson's disease

The effects of amantadine on traumatic brain injury outcome: a double-blind, randomized, controlled, clinical trial

Noradrenergic Modulation of Saccades in Parkinson's Disease

Early Amantadine Treatment Reduces the Risk of Death in Patients With Large Hemisphere Infarctions

The effectiveness of dopamine agonists for treatment of neuropsychiatric symptoms post brain injury and stroke